In vivo delivery of bionanocapsules displaying Phaseolus vulgaris agglutinin-L4 isolectin to malignant tumors overexpressing N-acetylglucosaminyltransferase V

Human Gene Therapy
Takeshi KasuyaShun'ichi Kuroda

Abstract

Metastasis is a key aspect of tumor malignancy, and several malignant tumors show expression of various mature N-type glycans. In particular, beta1-6 branching N-acetylglucosamine (GlcNAc) is abundantly expressed as a part of high-mannose glycans in various highly metastatic cancers. Phaseolus vulgaris agglutinin-L(4) isolectin (L(4)-PHA), which adheres to beta1-6 GlcNAc specifically, has been used for in situ cancer diagnosis. Bionanocapsules (BNCs), hollow particles with a diameter of approximately 80 nm and composed of hepatitis B surface antigen (HBsAg) and a lipid bilayer, have been developed as human liver-specific nanocapsules for in vivo drug delivery system. In this study, we have generated L(4)-PHA-displaying BNCs (PHA-BNCs) and examined whether L(4)-PHA could retarget the BNCs to malignant tumors as a "biosensor" distinguishing tumor metastaticity. Fluorescence-labeled PHA-BNCs injected systemically into a mouse xenograft model were found to accumulate in beta1-6 GlcNAc-expressing malignant tumors. The PHA-BNCs were able to deliver DNA to the malignant cancer cells. These results open up the possibility of using L(4)-PHA lectin as a targeting molecule in a drug delivery system, and of using PHA-BNCs as a novel nanode...Continue Reading

References

Jan 1, 1989·Advances in Cancer Research·S Hakomori
Jan 1, 1988·Critical Reviews in Clinical Laboratory Sciences·A Raedler, S Schreiber
Apr 1, 1994·Journal of Virology·H MehdiM E Peeples
Aug 1, 1997·The Journal of Biological Chemistry·P BuckhaultsM Pierce
May 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·S K HobbsR K Jain
Aug 7, 1999·The Journal of Biological Chemistry·J H KoN Taniguchi
Dec 2, 1999·Biochimica Et Biophysica Acta·J W DennisC E Warren
Mar 4, 2000·Nature Medicine·M GranovskyJ W Dennis
Jun 1, 1997·Cancer Biotherapy & Radiopharmaceuticals·B M Wimer
Nov 6, 2002·Biochimica Et Biophysica Acta·James W DennisMichael Demetriou
Jul 2, 2003·Nature Biotechnology·Tadanori YamadaShun'ichi Kuroda
Aug 23, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Amado J ZuritaRenata Pasqualini
Mar 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hirotoshi Dosaka-AkitaNaoyuki Taniguchi
Sep 29, 2004·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ling GengDennis Hallahan
Jan 28, 2006·Analytical and Bioanalytical Chemistry·Nathaniel G Portney, Mihrimah Ozkan
Sep 23, 2006·Cancer Gene Therapy·Y IwasakiM Kitajima
Dec 19, 2006·Molecular Cancer Therapeutics·Christopher R Ireson, Lloyd R Kelland
Aug 19, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yumi TsutsuiHideki Matsui
Oct 9, 2007·Biochimica Et Biophysica Acta·Christoph Schliemann, Dario Neri
Jan 22, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Joohee JungShun'ichi Kuroda

❮ Previous
Next ❯

Citations

Feb 25, 2009·Expert Opinion on Drug Delivery·Takeshi Kasuya, Shun'ichi Kuroda
Mar 26, 2013·Journal of Virological Methods·Yuya NishimuraAkihiko Kondo
Oct 21, 2015·Advanced Drug Delivery Reviews·Masaharu Somiya, Shun'ichi Kuroda
Feb 9, 2010·Nanomedicine : Nanotechnology, Biology, and Medicine·Jeong-Hun KangYoshiki Katayama
Oct 4, 2011·Journal of Biotechnology·Yuya NishimuraAkihiko Kondo
Feb 24, 2009·Journal of the American College of Cardiology·Hiroyuki TakahamaMasafumi Kitakaze
Nov 8, 2016·Biosensors & Bioelectronics·Masumi Iijima, Shun'ichi Kuroda
Nov 22, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Mitsuo YamadaShun'ichi Kuroda

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Biosensors for Cancer Detection

Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.

Related Papers

Journal of Controlled Release : Official Journal of the Controlled Release Society
Joohee JungShun'ichi Kuroda
Bioorganic & Medicinal Chemistry Letters
Takuya ShishidoAkihiko Kondo
© 2022 Meta ULC. All rights reserved